



## Technical Bulletin



Date: January 19, 2021  
Topic: Moderna Vaccine Lot 41L20A and higher incidence of adverse reactions  
Contact: Ihsan Azzam, Ph.D., M.D., Chief Medical Officer, [iazzam@health.nv.gov](mailto:iazzam@health.nv.gov)  
To: COVID-19 Vaccine Providers

---

### Situation:

According to various reports, numerous health care workers who received the Moderna vaccine at Petco Park in San Diego last week had severe allergic reactions. Out of an extreme abundance of caution and due to extremely limited supplies of the COVID-19 vaccines, the California Department of Public Health recommended that providers use other available vaccine inventory and pause the administration of vaccines from Moderna Lot 041L20A until the investigations by CDC, FDA, Moderna and the state of California are completed. It is important to emphasize that **no similar observations or additional clusters have been reported in other states including Nevada**, even though providers in Nevada and Washington State administered Moderna vaccines from that same suspected Moderna lot.

### Summary of CDC Guidance for the use of Moderna Lot 041L20A

The Nevada State Immunization Program promptly and proactively requested urgent guidance from Moderna and the CDC. However, the CDC reported back that they do not have enough documentation or information at this time, and they/CDC recommended that practices should remain unchanged. Currently, the vaccine manufacturer, CDC and FDA are promptly reviewing that Moderna vaccine lot and other related medical information.

### Recommendations from the Nevada Division of Public and Behavioral Health

At this time, it is recommended that all individuals who are vaccinated with Moderna Vaccine Lot 041L20A be observed for **30 minutes** after vaccination. All vaccination sites should be following CDC guidelines and be prepared to handle anaphylaxis or other immediate adverse reactions. The manufacturer, Centers for Disease Control and Prevention (CDC) and U.S. Food and Drug Administration (FDA) are thoroughly reviewing the suspected Moderna Vaccine lot and related medical information. The Nevada State Immunization Program is monitoring the vaccination process in our state and is closely communicating with the CDPH and other Western states that received the same Moderna Vaccine lot. Based on the Moderna, CDC, and FDA feedback, the four Western States Vaccination Safety Review Working Group may need to hold an urgent meeting to review the findings from the investigation in California and provide focused advice and recommendations to California and our Western States.

We will provide updates as they become available. Please let us know if you have any additional advice or recommendations.

**Resources:**

Anaphylaxis management:

[https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html?CDC\\_AA\\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fpfizer%2Fanaphylaxis-management.html](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fpfizer%2Fanaphylaxis-management.html)

mRNA vaccine information:

[https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html?CDC\\_AA\\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fpfizer%2Fclinical-considerations.html](https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fpfizer%2Fclinical-considerations.html)

Moderna Fact Sheet for Providers (package insert)

<https://www.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf>

***Questions:***

*For updated guidance, please review the DPBH Technical Bulletin [website](#) and Nevada's health response [website](#) regularly.*



Lisa Sherych, Administrator  
Division of Public and Behavioral Health



Ihsan Azzam, Ph.D., M.D.  
Chief Medical Officer